ABSTRACT
INTRODUCTION
There has been an increasing trend of delivery of drugs by the airways (1) . A recent example is the administration of small peptides such as insulin (2) . The present study is the first to describe cancer chemotherapy by inhalation. The anticancer drug is delivered by aerosolization in a liposome formulation using dilauroylphosphatidylcholine (DLPC) . No significant toxic effects were observed in trials of DLPC liposome-only aerosols in dogs and volunteers (3, 4) . 9-nitro-20(S)-camptothecin (9NC), a water-insoluble camptothecin (CPT) analogue with potent antitumor effects in mice and modest antitumor effect in humans when administered orally (it is not available for i.v. use), was formulated in the DLPC liposome (5, 6) . CPTs are not vesicant and can be administered by various routes, including intrathecally (7) . In mouse xenograft and pulmonary metastasis models, the equieffective 9NC dose with aerosol administration of liposomal 9NC (DLPC-9NC) was lower than the dose required by other routes of administration (8) . On the basis of these successful experiments, DLPC-9NC was selected for human trials.
The first objective of this study was to determine the safety and feasibility of aerosol administration of DLPC-9NC to human patients for 5 consecutive days/week for increasing periods of time. Secondary study objectives included determinations of the recommended Phase II dose for an 8-week course of treatment and the dose-limiting toxicity (DLT) profile for this length of administration. Concentrations of 9NC in plasma of volunteering patients were measured to determine preliminary pharmacokinetics of the aerosolized preparation. predicted values. All patients signed an informed consent form approved by the human-subject institutional review board.
Treatment. 9-Nitrocamptothecin (ChemWerth, Woodbridge, CN) and dilauroylphosphatidylcholine (Avanti Polar Lipids, Alabaster, AL) were formulated by S.P. Pharmaceuticals LLC (Albuquerque, NM) and lyophilized to a dry powder as described previously (4) . Sterile vials of 2 mg of 9NC and 100 mg of DLPC were stored at Ϫ20°C until ready for patient use. The drug was mixed with 10 ml of sterile water that provided an approximate 30-min nebulization treatment.
A feasibility evaluation of DLPC-9NC administered 5 consecutive days/week by aerosol was done first, followed by a Phase I trial. Six patients (cohort 1) were entered in the feasibility cohort and treated twice for 30 min every day for 5 consecutive days, followed by an observation period of 2 weeks. The daily dose was 6.7 g/kg 9NC. Once the feasibility of the aerosol treatment was established, the Phase I study began, first by increasing the number of weeks of delivery with 1 patient/ each test period followed by 2 weeks of observation. The test periods were 2, 4, and 6 weeks (cohorts 1A, 1B, and 1C). Dose escalation started with 8 weeks of administration with cohorts of 3-6 patients (cohorts 2-5). Increasing drug dosage from 6.7 g/kg/day was done first by doubling the concentration of drug in the nebulizer, then by increasing the amount of time/daily administration. Estimated daily doses tested were 6.7, 13.3, 26.6, and 20.0 g/kg/day (Table 1 ; Ref. 9). The drug was administered through an AeroMist nebulizer (CIS-US, Bedford, MA) flowing at 10 liters of air/min with a mouth breathing-only face mask (Hans Rudolph, Inc., Kansas City, MO). Patients and the aerosol nebulizer were enclosed in a HEPA-filtered airborne scavenging tent (Peace Medical, Inc., Orange, NJ). Premedication was introduced after 1 patient (cohort 2) developed a grade 2 bronchial irritation after a treatment. Patients in later cohorts were premedicated for 3 days before starting chemotherapy with Albuterol and Fluticasone propionate inhalers, which were then given on an as needed basis throughout the aerosol treatment period. Before chemotherapy administration, patients simulated a treatment to familiarize themselves with the tent environment, face mask, and respiratory techniques. The first 8-week course and the first week of the second course of treatment were administered at M. D. Anderson Cancer Center under clinical supervision to observe and train patients. Afterward, if no side effects greater than grade 2 were observed, patients were allowed to self administer treatment at home with a portable air compressor (Easy Air 15; Precision Medical, Northampton, PA) and an Enviracaire HEPA-filtering system (Honeywell, Golden Valley, MN). Home treatment was supervised weekly by telephone contact and once by a home visit by a member of the research team. Repeated courses at the same or the previous dose level were administered to the patients who benefited from the treatment as determined by either remission or stabilization of disease.
Follow-Up. Patients were followed every 3-4 weeks with a complete medical history, a physical examination, including performance status, weekly complete blood-cell counts, monthly blood chemistries, and urinalysis. Tumor markers and a computer-assisted tomography scan of the chest were obtained at baseline and before each course. All radiographic imaging data of responding patients were reviewed by an independent radiologist (E. Loyer) and by the principal investigator (C. F. Verschraegen). Simple spirometry, DLCO, and lung volumes were performed according to American Thoracic Society standards (10) before and after the first aerosol exposure (within 2 h) and more frequently if clinically indicated to detect pulmonary functional abnormalities. Pulse oximeter readings were recorded daily. If the spirometry was within normal values, lung volumes and DLCO were not always repeated.
Pharmacological Procedures. Because this was the first use of 9NC as an aerosol, it was important to determine systemic absorption after inhalation. For subjects who volunteered for pharmacokinetic studies, blood was obtained at various time points from the start of the aerosol treatment depending on the cohort. For cohort 1 (feasibility study), blood was obtained on either day 5 of the treatment week. Samples were taken at 0, 0. Extraction of total 9NC and its carboxylate and lactone forms were performed using Waters C18 Sep-Pak Light cartridges immediately after separating the plasma. The cartridges were activated with 1 ml of 100% methanol, followed by 1 ml of water. Fifty l of the lactone form of CPT in 100% methanol (CPT; final concentration, 5 or 10 ng CPT/ml) were added as internal standard to 1 ml of plasma in a 3-ml syringe. This sample was immediately loaded onto the cartridge. The fraction that did not bind to the cartridge was collected as the carboxylate form of 9NC. Then the C18 cartridge was washed with 1 ml of water, followed by 1 ml of 20% methanol in water, and the lactone form (containing the internal standard) was collected by eluting the cartridge with 1 ml of 100% methanol. Another 1 ml of plasma was used to extract the total 9NC.
For cohorts 1, 1A, 1B, and 2, liquid chromatography/mass spectrometry (MS) analysis (see below) was used to detect all 9NC fractions and done at M. D. Anderson Analytical Core Laboratory. The following extraction technique was used. Fifty l of CPT and 2 ml of acetonitrile were added to 1 ml of the carboxylate eluate, and to 1 ml of plasma (total 9NC fraction), the mixtures vortexed for 5 min and then centrifuged for at 2500 rpm for 5 min in a refrigerated (4°C) centrifuge. Five ml of a 95:5 mixture of chloroform:2-propanol (v/v) were added to the supernatants, vortexed for 5 min, and then centrifuged for at 2500 rpm for 5 min. The lower layer was placed into glass tubes and placed in a heating block at 40°C and evaporated to dryness with air. The lactone eluate was also dried. All three 9NC fractions were reconstituted with 50 l of 100% methanol, vortexed briefly, and then 50 l of 0.02% formic acid were added and vortexed. After centrifugation at 2500 rpm for 5 min, the supernatants were centrifuged again in a microfuge at 15,000 rpm for 5 min. The resulting supernatant fractions were used for LC/MS analysis. For cohorts 3, 4 and 6, a high-performance liquid chromatography detection method was used at Baylor College of Medicine. Fifty l of CPT was added to 1 ml of plasma and to 1 ml of carboxylate eluate as described above and the mixture vortexed for 10 s. To precipitate protein and acidify the fraction to convert all 9NC to the lactone form, 1 ml of 8.5% H 3 PO 4 was added, vortexed, and allowed to incubate for 15 min at room temperature. After centrifugation (International Electrotechnical Commission centrifuge; 2000 rpm for 10 min), the supernatants were loaded onto C18 Sep-Pak cartridges and processed as described above. The 9NC was collected as the lactone form in the 100% methanol fraction. An aliquot (0.5 ml) of all three 9NC fractions was added to 15-ml plastic centrifuge tubes, placed in a heating block at 50°C, and evaporated to dryness with air. The samples were reconstituted 5-fold by adding 100 l of high-performance liquid chromatography mobile phase as described below. The reconstituted samples were centrifuged in a microfuge at 13,000 rpm for 10 min and the supernatants used.
The LC/MS instrument (MicroMass, Beverly, MA) was operated in the electrospray-positive ionization mode. 9NC and CPT (internal standard) were detected in selected ion recording mode at m/z 394 for 9NC and m/z 349 for CPT. Analytes were separated from background plasma components by running extracted samples through a microbore YMCbasic 5-m 1 ϫ 100-mm analytical column (Waters, Milford, MA). Column temperature was maintained at 30°C. The isocratic mobile phase consisted of 40% acetonitrile and 60% 0.1% formic acid (aqueous; pH 3.0) at a flow rate of 100 l/min. The lowest level of detection for 9NC was 0.5 ng/ml plasma.
The Waters HPLC system used a Waters Xterra MS C-18 guard column with a Waters Xterra MS C-18 column (2.1 ϫ 150 mm) heated to 50°C. The isocratic mobile phase consisted of 40% methanol and 60% water containing 0.5% acetic acid (pH 1.5) flowing at 0.25 ml/min. 9NC was detected using a Waters 2487 absorbance detector set at 228 nm, whereas CPT was detected using a Waters 470 scanning fluorescence detector (excitation wavelength, 360 nm; emission wavelength, 455 nm). Minimal level of detection was 2.5 ng 9NC/ml plasma. Selected samples were compared with the LC/MS method and found to be equivalent.
Standard curves for 9NC were prepared in human serum and processed as described above for each cohort. Concentrations of 0, 0.5, 2.5, 10, 50, 100, and 250 ng 9NC/ml of plasma each containing 10 ng CPT/ml as the internal standard were used. 9NC plasma concentrations were calculated from the ratio of 9NC to CPT.
Bronchoscopsy was performed by a pulmonologist (A. Huaringa) to obtain bronchoalveolar lavage (BAL) fluid from the right middle lobe of volunteering patients at various times after the completion of treatment. Concentration of total 9NC in the BAL fluid was corrected for dilution by determining the ratio of urea in the lavage and in a plasma sample taken at the same time (urea diffuses freely). Criteria for Response and Toxicity. Adverse events and DLTs occurring in the first course of therapy were based on the National Cancer Institute Common Toxicity Criteria version 2 to determine the appropriate starting dose for Phase II studies. DLTs were defined as the dose that produced a reversible grade 3 or 4 hematological toxicity lasting Ͼ7 days or a reversible grade Ն 3 (grade 2 for neurotoxicity) nonmyelosuppressive toxicity in Ͼ33% of patients treated at a given dose level. Clinical responses were determined according to the WHO criteria (11) .
Statistical Analysis. A standard 3 ϩ 3 design was used. The recommended dose for Phase II study was defined to be the highest dose for which no patient of 3 or Ͻ2 patients of 6 developed a grade Ն 3 toxicity.
Pulmonary function was compared by the two-tailed, paired t test to evaluate changes during and after treatment from baseline values. Total 9NC concentrations in plasma between cohorts were compared by two-tailed t test with unequal variances.
RESULTS
Of the 25 patients studied, 24 completed the protocol. One patient refused additional therapy after 15 min of the initial aerosol treatment because of claustrophobia in the tent environment. The characteristics of the 25 patients entered in the study are shown in Tables 2 and 3 . Mean FEV 1 and other pulmonary functions before treatment were at least Ն85% of predicted values.
At 26.6 g/kg/day, the DLT was a chemical pharyngeal mucositis seen at the end of the first week in 2 patients and necessitating an early treatment discontinuation. Recovery was prompt after stopping treatment (within 1 week). No changes in pulmonary function were observed in these patients. This cohort was halted, and a new cohort of 5 patients at a dose of 20.0 g/kg/day was started. One of these patients declined additional therapy after 1 week because he wanted to return to his home country. Two of the remaining 4 patients (males) completed treatment with few side effects, but the last 2 patients (females) required a dose reduction for grades 2 and 3 fatigue after 4 weeks of treatment. At doses of 13.3 g/kg/day, all patients tolerated the treatment well.
All other side effects were grades 1 or 2. Table 4 shows the main side effects, with cough in 67% of patients, bronchial irritation in 46%, sore throat in 33%, nausea in 62%, vomiting in 33%, anorexia in 33%, dysgeusia in 33%, fatigue in 50%, anemia and neutropenia in 29%, and skin rash around the face mask in 21%. Grade 1 epistaxis, chills, dysuria, and thrombocytopenia were seen in Յ4 patients. No grade Ն 3 neutropenia was observed. No cumulative toxic effects were observed in 7 patients who received more than one course.
There was a decrease in pulmonary function tests during treatment. Except for 3 patients, the greatest reductions for FEV 1 , FVC, TLC, and DLCO (Table 3) and O 2 saturation (data not shown) remained within an acceptable clinical range (Ͼ50% predicted value). Mean percent predicted FEV 1 function dropped by 20% during aerosol therapy (P Ͻ 0.0001) and improved to 83% of predicted value upon cessation of therapy (Fig. 1) . The mean end-of-treatment value was not significantly different from the baseline (P ϭ 0.107). The 3 patients with a FVC and/or FEV 1 Ͻ 50% of predicted value had extensive pulmonary tumor involvement at the start of treatment that was progressive despite therapy. TLC values were virtually unchanged and DLCO values were closely comparable with FVC results.
A partial remission was observed in 2 patients with endometrial carcinoma metastatic to the lung only. Both patients had been treated with surgery and pelvic radiotherapy, and one of them had also received adjuvant chemotherapy. Recurrence in the lungs occurred after 8 and 3 years, respectively. The remission was noted after the 8 first weeks of treatment (Fig. 2A) . The first patient was treated at 13.3 g/kg/day. The second at 20 g/kg/day for 4 weeks, then at 13 g/kg/day for the last 4 weeks. This reduction was prompted by a grade 2 fatigue, at the request of the patient. They both successfully underwent resection of the residual disease after two courses and remain free of cancer 18 months later. A partial remission of a liver metastasis was also observed in a patient with endometrial cancer treated at 13.3 g/kg/day, demonstrating the systemic potential of aerosol delivery of this drug (Fig. 2B ). In addition, 3 of the 6 patients with primary lung cancer had stabilization of their tumors. Two of these patients received 6.7 g/kg/day dose for either multiple 1-week courses or a 6-week course of treatment. The third patient received 13.3 g/kg/day dose for an 8-week course. Clinical evaluation of tumor mass was made during the follow up period from a computer-assisted tomography scan after either two 1-week courses or after a single 6-or 8-week course of treatment.
Of the 6 patients in the first cohort (6.7 g/kg/day), 5 volunteered for pharmacokinetic studies (12) . 9NC measured as total 9NC was detected in plasma at the first time point midway through the 1-h aerosol exposure (Fig. 3A) . Total 9NC plasma concentrations continued to increase for 2-3 h from the start of treatment reaching a mean (ϮSD) peak concentration of 37.7 Ϯ 20.2 ng/ml at 2 h (range, 13.6 -58.0 ng/ml). Mean (ϮSD) clearance of 9NC was biphasic with a T 1/2 ␣ of 1.9 Ϯ 1.4 h and a T 1/2 ␤ of 16.4 Ϯ 10.5 h. The area-under-the-curve (AUC) of the lactone form measured in the last 2 patients comprised only 3.2 and 3.5% of the total 9NC. Four of these 5 patients also volunteered for a bronchoscopy. The time of sampling was spread out among the patients from 1.2 to 4.8 h from the start of aerosol treatment. BAL 9NC concentrations varied from 51 to Ͼ361 ng/ml. Because of the large dilutions, urea levels in the BAL fluids were below detection (i.e., Ͻ0.5 mg/dl). Therefore, 9NC concentrations in BAL fluids were Ͼ4.2 to Ͼ10.6 times higher that those measured concurrently in the plasma.
To compare the effect of estimated deposited 9NC dosage on plasma drug levels, common time points were selected for all cohorts. A comparison of plasma drug levels at 0 (before start of treatment), 2, and 5 h from the start of aerosol treatment was chosen. Analysis of the AUC 0 -5 curve over a 5-h period was determined using the trapezoidal rule. As the estimated daily deposited 9NC aerosol dose was increased from 6.7 to 20.0 g/kg, there appeared to be a dose-dependent increase in 9NC plasma levels at the two lower doses, although the differences were not statistically significant with the small number of patients studied (Fig. 3B) . Similar changes were observed in both C MAX and AUC results. A, total 9NC plasma pharmacokinetics in patients treated with 6.7 g 9NC/kg/day as a liposome aerosol using mouth-only breathing. Patients were treated for 1 h for 5 consecutive days, and plasma samples were obtained on day 5 (last day of treatment). B, effect of dose after one week of treatment on total 9NC plasma pharmacokinetics in volunteers after 9NC liposome aerosol administered p.o.-only breathing. n ϭ number of patients. C MAX is the maximum plasma concentration measured over a 5-h period after the start of treatment. Area-under-the-curve (AUC) was determined for the common 5 h period from the start of treatment of the patients.
DISCUSSION
Previous clinical studies of 9NC have used oral administration. In these studies, the main toxicity profile of 9NC was hematological with anemia and neutropenia and gastrointestinal with nausea, vomiting, and anorexia (13, 14) . Another difficult side effect of oral administration was chemical cystitis with hematuria (14) . In the present study, the most remarkable finding was the lack of hematological toxicity, the mechanism for which we do not yet have an explanation. Although aerosol doses were lower than those administered orally, 9NC plasma levels were similar to those observed after oral ingestion. After aerosolization, the C MAX at the Phase II recommended dose (i.e., 13.3 g/kg/day, equivalent to 0.5 mg/m 2 /day) was 76.7 Ϯ 39.1 ng/ml (range, 32.0 -120.4 ng/ml), and the AUC was 275 Ϯ 149 ng-h/ml, and after oral administration of 2 mg/m 2 , C MAX was 111 ng/ml (range, 26 -517 ng/ml), and the AUC was 194.4 Ϯ 108.4 ng-h/ml (14, 15) . The DLT at 26.6 g/kg/day was a chemical pharyngitis. The other dose-limiting effect at 20.0 g/kg/day was a generalized fatigue accompanied by muscle aches, as expected with cellular poisons. Interestingly, grade Յ 2 fatigue was seen at all dose levels. Although the most dramatic dose-limiting toxicity was chemical pharyngitis, the mucosa of the bronchus was spared significant toxicity despite a reversible decrease in FEV 1 . Cough and bronchial irritation were clinically ameliorated by bronchodilators and steroids. Bronchial irritation was also more pronounced in patients with extensive pulmonary involvement with cancer. Changes in oxygen saturation and lung volumes were not clinically relevant. This study was limited in time because of the nature of the diseases treated; therefore, we do not have data on long-term pulmonary toxicity. It is encouraging that FEV 1 values were reversible after cessation of treatment (Fig. 1) . Nausea and vomiting were observed in a few patients, but these complaints did not reach the intensity seen with oral administration (14, 16) , and weight loss was not observed after aerosol delivery. Although 2 patients complained of dysuria, blood was not seen on the urine microscopic examination.
Our pharmacology results demonstrated that there was a dose-dependent increase in both C MAX and AUC values at the two lower doses but not at the highest dose. This may have been due to a saturation effect on the lungs' ability to transport drug from the alveolar side to the blood. Such an effect would be detected best in AUC values. Although the 9NC plasma AUC value at the highest dose was greater than the increase in the 9NC aerosol dose, the limited number of patients and time points prevented an accurate analysis. Future pharmacology studies will follow patients for longer periods of time. Our results also show that high levels of 9NC were found in the lungs at the end of treatment and that higher BAL to plasma ratios were noted at later time points. One weakness of our study is the commercial urea measurement in the BAL, which fell below the detection level of common laboratory techniques. Absorption of drug through the lung parenchyma into the systemic circulation after its inhalation is rapid and sustained. Alveolar-capillary exchange of drug is through the pulmonary vein, making inhalation therapy a method of sustained arterial delivery. This would allow first pass presentation of drug to cancer sites. It is also possible that 9NC deposited on lung surfaces is metabolized differently than after other routes of administration. The aerosol droplet size of the 9NC liposomal complex is in the range that optimizes alveolar deposition (1-3 m).
Responses were observed in patients with endometrial cancer at the recommended Phase II dose, not only in the lungs, but also systemically. Responses occurred early after initiation of chemotherapy (within the first 4 weeks by chest X-ray, confirmed at 8 weeks by computerized tomography scanning) and led to resection of pulmonary disease with a possibility of cure in 2 patients as recommended (17) .
The recommended dose for Phase II studies is 13.3 g/kg/ day on a daily 60-min exposure, 5 consecutive days/week for 8 weeks, with a concentration of 9NC of 0.4 mg/ml in the nebulizer. The advantages of inhaled 9NC are rapid and efficient systemic absorption and the good side effect profile. Because of the promising anticancer activity, a Phase II study in patients with recurrent endometrial cancer is planned. Additional pharmacokinetics will also be performed to better define the disposition of 9NC after inhalation in plasma, tumor, and bronchoalveolar fluids.
